A once-daily dose of ivarmacitinib reduced disease activity and improved function among patients with rheumatoid arthritis through 52 weeks, according to phase 3 trial results published in Annals of ...

Since entering the allergy field, Priya J. Bansal, MD, FAAAAI, FACAAI, has seen positive changes, including the entry of more ...

A Minnesota mom will spend less than four years in prison after pleading guilty to manslaughter after she and her husband ...

Despite advances in the treatment of patients with the most severe forms of asthma, progress remains to be made as half of ...